explore -WSS

explore

author：entertainment 2025-09-02 22:09:18 - browse：68288

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Akili changes sales model for its ADHD video game treatment

hotspot

focus

WSS

Why the drug industry's warnings on the IRA's impact fall short

Transgender sports debate: Physicians say bans are health issue

Phenylephrine and the overlooked value of the placebo effect

Grad students accuse University of California of wage theft

Chamber of Commerce, DOJ clash in court over drug prices

How the messy conversation about Dolly changed bioethics

focus

explore

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Covid’s new normal has set in amid another rise in cases

As demand for Covid shots wanes, Moderna seeks its next success

Midwives could help bridge maternal health disparities in the U.S.

Bright Health sells Medicare Advantage business to Molina

Stroke deaths set to near 10 million globally by 2050

How to save PrEP access — and even expand it

Bill would stop addiction treatment from triggering child abuse inquiry

In Memoriam: Notable people who died in 2023

How the messy conversation about Dolly changed bioethics

hotspot

Chamber of Commerce, DOJ clash in court over drug prices

How the messy conversation about Dolly changed bioethics

Bill would stop addiction treatment from triggering child abuse inquiry

A virus, fished out of a lake, may have saved a man’s life

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

What to expect at HLTH 2023, the health care industry conference

hotspot

explore

focus

hotspot